ArticleRadiation oncology (London, England)2020

The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.

Alexander Rühle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.